
Lilly bets on prevention with triple acquisitions to boost infectious-disease portfolio
Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Company to broaden its infectious-disease portfolio, spanning a shingles vaccine candidate, a bacterial-pathogen vaccine platform, and an EBV-focused virus-like particle vaccine, for up to about $3.83 billion in cash and milestone payments, subject to closing conditions.












